drugset / Trial / NCT04325672
Convalescent Plasma to Limit Coronavirus Associated Complications
NaSingle-groupOpen-labelBasic science
Summary
Researchers are trying to assess the treatment potential and safety of anti-SARS-CoV-2 convalescent plasma in patients with acute respiratory symptoms with confirmed COVID-19.
Timeline
- Start
- 2020-04-01
- Primary completion
- 2022-12-31
- Completion
- 2022-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Convalescent Plasma | Protein / enzyme biologic | 300 ml | — |
| Subject | Convalescent Plasma | Protein / enzyme biologic | 600 ml | — |